View Filing Data

Document and Entity Information	6 Months Ended
Document and Entity Information	Jun. 30, 2020
Document And Entity Information
Entity Registrant Name	BioLineRx Ltd.
Entity Central Index Key	0001498403
Document Type	6-K
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2020

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION (UNAUDITED) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
CURRENT ASSETS
Cash and cash equivalents	$ 5,523	$ 5,297
Short-term bank deposits	21,779	22,192
Prepaid expenses	426	108
Other receivables	441	613
Total current assets	28,169	28,210
NON-CURRENT ASSETS
Property and equipment, net	1,580	1,816
Right-of-use assets, net	1,490	1,650
Intangible assets, net	21,750	21,891
Total non-current assets	24,820	25,357
Total assets	52,989	53,567
CURRENT LIABILITIES
Current maturities of long-term loans	2,867	2,692
Accounts payable and accruals:
Trade	7,396	7,794
Other	1,260	1,280
Lease liabilities	200	202
Total current liabilities	11,723	11,968
NON-CURRENT LIABILITIES
Warrants	6,077	658
Long-term loans, net of current maturities	4,329	5,799
Lease liabilities	1,630	1,762
Total non-current liabilities	12,036	8,219
COMMITMENTS AND CONTINGENT LIABILITIES
Total liabilities	23,759	20,187
EQUITY
Ordinary shares	8,281	4,692
Share premium	271,107	265,938
Capital reserve	12,639	12,132
Other comprehensive loss	(1,416)	(1,416)
Accumulated deficit	(261,381)	(247,966)
Total equity	29,230	33,380
Total liabilities and equity	$ 52,989	$ 53,567

CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Profit or loss [abstract]
RESEARCH AND DEVELOPMENT EXPENSES	$ (4,640)	$ (5,302)	$ (10,062)	$ (9,694)
SALES AND MARKETING EXPENSES	(182)	(226)	(357)	(482)
GENERAL AND ADMINISTRATIVE EXPENSES	(744)	(949)	(1,987)	(1,879)
OPERATING LOSS	(5,566)	(6,477)	(12,406)	(12,055)
NON-OPERATING INCOME (EXPENSES), NET	(843)	1,261	(374)	921
FINANCIAL INCOME	35	171	175	381
FINANCIAL EXPENSES	(396)	(440)	(810)	(887)
NET LOSS AND COMPREHENSIVE LOSS	$ (6,770)	$ (5,485)	$ (13,415)	$ (11,640)
LOSS PER ORDINARY SHARE - BASIC AND DILUTED	$ (0.03)	$ (0.04)	$ (0.07)	$ (0.08)
WEIGHTED AVERAGE NUMBER OF SHARES USED IN CALCULATION OF LOSS PER ORDINARY SHARE	220,317,889	145,461,598	198,277,447	139,270,178

CONDENSED INTERIM STATEMENTS OF CHANGES IN EQUITY (UNAUDITED) - USD ($) $ in Thousands	Ordinary shares [Member]	Share premium [Member]	Capital reserve [Member]	Other comprehensive loss [Member]	Accumulated deficit [Member]	Total
BALANCE at Dec. 31, 2018	$ 3,110	$ 250,192	$ 11,955	$ (1,416)	$ (222,520)	$ 41,321
CHANGES FOR
Issuance of share capital, net	890	10,437				11,327
Employee stock options exercised	1	27	(27)			1
Employee stock options forfeited and expired		866	(866)
Share-based compensation			773			773
Comprehensive loss for the period					(11,640)	(11,640)
BALANCE at Jun. 30, 2019	4,001	261,522	11,835	(1,416)	(234,160)	41,782
BALANCE at Mar. 31, 2019	3,928	259,860	12,191	(1,416)	(228,675)	45,888
CHANGES FOR
Issuance of share capital, net	73	817				890
Employee stock options exercised		9	(9)
Employee stock options forfeited and expired		836	(836)
Share-based compensation			489			489
Comprehensive loss for the period					(5,485)	(5,485)
BALANCE at Jun. 30, 2019	4,001	261,522	11,835	(1,416)	(234,160)	41,782
BALANCE at Dec. 31, 2019	4,692	265,938	12,132	(1,416)	(247,966)	33,380
CHANGES FOR
Issuance of share capital, net	3,581	4,754				8,335
Employee stock options exercised	8	224	(224)			8
Employee stock options forfeited and expired		191	(191)
Share-based compensation			922			922
Comprehensive loss for the period					(13,415)	(13,415)
BALANCE at Jun. 30, 2020	8,281	271,107	12,639	(1,416)	(261,381)	29,230
BALANCE at Mar. 31, 2020	4,907	267,140	12,488	(1,416)	(254,611)	28,508
CHANGES FOR
Issuance of share capital, net	3,373	3,859				7,232
Employee stock options exercised	1	20	(20)			1
Employee stock options forfeited and expired		88	(88)
Share-based compensation			259			259
Comprehensive loss for the period					(6,177)	(6,770)
BALANCE at Jun. 30, 2020	$ 8,281	$ 271,107	$ 12,639	$ (1,416)	$ (261,381)	$ 29,230

- Definition

The amount of residual interest in the assets of the entity after deducting all its liabilities.

+ References + Details

- Definition

The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 7
-IssueDate 2019-01-01
-Paragraph 18
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=7&code=ifrs-tx-2019-en-r&anchor=para_18_b&doctype=Standard
-URIDate 2019-03-27

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 24
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_24_b&doctype=Standard
-URIDate 2019-03-27

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 1
-IssueDate 2019-01-01
-Paragraph 32
-Subparagraph a
-Clause ii
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2019-en-r&anchor=para_32_a_ii&doctype=Standard
-URIDate 2019-03-27

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 28
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_28_b&doctype=Standard
-URIDate 2019-03-27

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Note Effective on first application of IFRS 9
-Name IFRS
-Number 4
-IssueDate 2019-01-01
-Paragraph 39L
-Subparagraph e
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2019-en-b&anchor=para_39L_e&doctype=Standard
-URIDate 2019-03-27

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 8
-IssueDate 2019-01-01
-Paragraph 23
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2019-en-r&anchor=para_23&doctype=Standard
-URIDate 2019-03-27

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Name IFRS
-Number 12
-IssueDate 2019-01-01
-Paragraph B10
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B
-URIDate 2019-03-27

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 106
-Subparagraph d
-Clause i
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_i&doctype=Standard
-URIDate 2019-03-27

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Note Effective 2021-01-01
-Name IFRS
-Number 17
-IssueDate 2019-01-01
-Paragraph 113
-Subparagraph b
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2019-en-r&anchor=para_113_b&doctype=Standard
-URIDate 2019-03-27

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name IAS
-Number 1
-IssueDate 2019-01-01
-Paragraph 81A
-Subparagraph a
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_81A_a&doctype=Standard
-URIDate 2019-03-27

+ Details

CONDENSED CONSOLIDATED INTERIM CASH FLOW STATEMENTS (UNAUDITED) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS - OPERATING ACTIVITIES
Comprehensive loss for the period	$ (13,415)	$ (11,640)
Adjustments required to reflect net cash used in operating activities (see appendix below)	1,112	573
Net cash used in operating activities	(12,303)	(11,067)
CASH FLOWS - INVESTING ACTIVITIES
Investments in short-term deposits	(23,751)	(27,510)
Maturities of short-term deposits	24,335	24,441
Purchase of property and equipment	(1)	(53)
Net cash provided by (used in) investing activities	583	(3,122)
CASH FLOWS - FINANCING ACTIVITIES
Issuance of share capital and warrants, net of issuance costs	13,411	15,879
Employee stock options exercised	8	1
Repayments of loans	(1,331)	(47)
Repayments of lease liabilities	(121)	(110)
Net cash provided by financing activities	11,967	15,723
INCREASE IN CASH AND CASH EQUIVALENTS	247	1,534
CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD	5,297	3,404
EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	(21)	34
CASH AND CASH EQUIVALENTS - END OF PERIOD	5,523	4,972
Income and expenses not involving cash flows:
Depreciation and amortization	533	439
Long-term prepaid expenses		(4)
Exchange differences on cash and cash equivalents	21	(34)
Fair value adjustments of warrants	(250)	(1,354)
Share-based compensation	922	773
Warrant issuance costs	593	417
Interest and exchange differences on short-term deposits	(171)	(440)
Interest on loans	36	292
Exchange differences on lease liability	(8)
Total income and expense not involving cash flows	1,676	89
Changes in operating asset and liability items:
Decrease (increase) in prepaid expenses and other receivables	(146)	848
Decrease in accounts payable and accruals	(418)	(364)
Total Change in operating asset and liability	(564)	484
Total Adjustments required to reflect net cash used in operating acivities	1,112	573
Supplemental information on interest received in cash	300	442
Supplemental information on interest paid in cash	$ 534	$ 477

GENERAL INFORMATION

6 Months Ended

Jun. 30, 2020

Disclosure of general information [Abstract]

GENERAL INFORMATION

NOTE 1 – GENERAL INFORMATION

General

BioLineRx Ltd. (“BioLineRx”), headquartered in Modi’in, Israel, was incorporated and commenced operations in April 2003.

BioLineRx and its subsidiaries (collectively, the “Company”) are engaged in the development of therapeutics, primarily in clinical stages, with a focus on the field of oncology.

In February 2007, BioLineRx listed its ordinary shares on the Tel Aviv Stock Exchange (“TASE”) and they have been traded on the TASE since that time. Since July 2011, BioLineRx’s American Depositary Shares (“ADSs”) have also been traded on the NASDAQ Capital Market.

In March 2017, the Company acquired Agalimmune Ltd. (“Agalimmune”), a privately held company incorporated in the United Kingdom, with a focus on the field of immuno-oncology.

Although it has generated revenues from out-licensing transactions in the past, the Company has incurred accumulated losses in the amount of $261 million through June 30, 2020, and cannot determine with reasonable certainty when and if it will have sustainable profits. Management believes that the Company’s current cash and other resources will be sufficient to fund its projected cash requirements through the end of 2021. However, in the event that the Company does not begin to generate sustainable cash flows from its operating activities in the future, the Company will need to carry out significant cost reductions or raise additional funding. Management regularly evaluates various financing alternatives, including funding its clinical development activities via out-licensing or collaborations, and fundraising in the public or private equity markets. However, there is no certainty about the Company’s ability to obtain such funding.

Approval of financial statements

The condensed consolidated interim financial statements of the Company as of June 30, 2020, and for the six months then ended, were approved by the Board of Directors on August 5, 2020, and signed on its behalf by the Chairman of the Board, the Chief Executive Officer and the Chief Financial Officer.

BASIS OF PREPARATION	6 Months Ended
BASIS OF PREPARATION	Jun. 30, 2020
Disclosure of basis of preparation [Abstract]
BASIS OF PREPARATION	NOTE 2 – BASIS OF PREPARATION The Company’s condensed consolidated interim financial statements as of June 30, 2020 and for the three and six months then ended (the “interim financial statements”) have been prepared in accordance with International Accounting Standard No. 34, “Interim Financial Reporting” (“IAS 34”). These interim financial statements, which are unaudited, do not include all disclosures necessary for a fair statement of financial position, results of operations, and cash flows in conformity with International Financial Reporting Standards (“IFRS”). The condensed consolidated interim financial statements should be read in conjunction with the Company’s annual financial statements as of December 31, 2019 and for the year then ended and their accompanying notes, which have been prepared in accordance with IFRS. The results of operations for the three and six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the entire fiscal year or for any other interim period. In the process of preparing the interim financial statements, management makes estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity and expenses, as well as the related disclosures of contingent assets and liabilities. These inputs also consider, among other things, the implications of COVID-19 on the Company’s activities, and the resultant effects on critical and significant accounting estimates, most significantly in relation to the value of intangible assets. The COVID-19 virus has spread to many countries throughout the world, including to the United States, Europe and Israel, where we currently have our therapeutic candidates manufactured and conduct our clinical trials. At present, we are experiencing some recruitment delays from the deepening and extended impact of COVID-19 on our clinical trials; however, at present, we do not believe these delays will significantly impact our clinical development plans. Future developments related to COVID-19 are highly uncertain, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat it, as well as its overall economic impact, and more specifically its effects on the financial markets. All estimates made by the Company related to the impact of COVID-19 in its financial statements may change in future periods. Actual results could differ from those estimates.

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
SIGNIFICANT ACCOUNTING POLICIES	Jun. 30, 2020
Disclosure of significant accounting policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	NOTE 3 – SIGNIFICANT ACCOUNTING POLICIES The accounting policies and calculation methods applied in the preparation of these interim financial statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2019 and for the year then ended.

AT-THE-MARKET (ATM) SALES AGREEMENT WITH BTIG	6 Months Ended
AT-THE-MARKET (ATM) SALES AGREEMENT WITH BTIG	Jun. 30, 2020
Disclosure of issuances of share capital and warrants [Abstract]
AT-THE-MARKET ("ATM") SALES AGREEMENT WITH BTIG	NOTE 4 – AT-THE-MARKET (“ATM”) SALES AGREEMENT WITH BTIG In October 2017, the Company entered into an at-the-market (“ATM”) sales agreement with BTIG, LLC (“BTIG”), pursuant to which the Company was entitled, at its sole discretion, offer and sell through BTIG, acting as sales agent, ADSs having an aggregate offering price of up to $30.0 million throughout the period during which the ATM facility remains in effect. The Company agreed to pay BTIG a commission of 3.0% of the gross proceeds from the sale of ADSs under the facility. During the six-month period ended June 30, 2020, the Company issued a total of 676,750 ADSs for total net proceeds of $1.4 million under the ATM facility. From the effective date of the agreement through June 30, 2020, an aggregate of 2,923,552 ADSs were sold under the facility for total gross proceeds of approximately $13.0 million. In April 2020, the Company filed a prospectus supplement reducing the available balance under the facility to approximately $8.5 million. In May 2020, in connection with the registered direct offering (see Note 5), the Company terminated the prospectus supplement and, accordingly, no sales may be made under the facility at the present time.

FINANCINGS

6 Months Ended

Jun. 30, 2020

Disclosure of classes of share capital [abstract]

FINANCINGS

NOTE 5 – FINANCINGS

In May 2020, the Company completed a registered direct offering of 5,142,859 ADSs at a price of $1.75 per ADS. In a concurrent private placement, the Company issued to investors in the offering unregistered warrants to purchase 5,142,859 ADSs. The warrants are exercisable immediately, expire two and half years from the date of issuance and have an exercise price of $2.25 per ADS. In addition, the Company granted to the placement agent’s designees, as part of the placement fee, warrants to purchase 257,143 ADSs. These warrants are exercisable immediately, expire two and half years from the date of issuance and have an exercise price of $2.1875 per ADS. The offering raised a total of $9.0 million, with net proceeds of $8.1 million, after deducting fees and expenses.

The warrants issued have been classified as a non-current financial liability due to a net settlement provision. This liability was initially recognized at its fair value on the date the contract was entered into and is subsequently accounted for at fair value at each balance sheet date. The fair value changes are charged to non-operating income and expense in the statement of comprehensive loss.

The fair value of the warrants is computed using the Black-Scholes option pricing model. The fair value of the warrants upon issuance was computed based on the then current price of an ADS, a risk-free interest rate of 0.20% and an average standard deviation of 80.2%.

In June 2020, the Company completed a registered direct offering of 2,510,286 ADSs at a price of $1.75 per ADS. In a concurrent private placement, the Company issued to investors in the offering unregistered warrants to purchase 2,510,286 ADSs. The warrants are exercisable immediately, expire two and half years from the date of issuance and have an exercise price of $2.25 per ADS. In addition, the Company granted to the placement agent’s designees, as part of the placement fee, warrants to purchase 125,514 ADSs. These warrants are exercisable immediately, expire two and half years from the date of issuance and have an exercise price of $2.1875 per ADS. The offering raised a total of $4.4 million, with net proceeds of $3.9 million, after deducting fees and expenses.

SHAREHOLDERS' EQUITY

6 Months Ended

Jun. 30, 2020

Disclosure of classes of share capital [abstract]

SHAREHOLDERS' EQUITY

NOTE 6 – SHAREHOLDERS’ EQUITY

As of December 31, 2019 and June 30, 2020, the Company’s share capital is composed of ordinary shares, as follows:

	Number of ordinary shares
	December 31,		June 30,
	2019		2020

Authorized share capital		500,000,000		500,000,000

Issued and paid-up share capital		171,269,528		296,508,550

	In USD and NIS
	December 31,		June 30,
	2019		2020

Authorized share capital (in NIS)		50,000,000		50,000,000

Issued and paid-up share capital (in NIS)		17,126,953		29,650,855

Issued and paid-up share capital (in USD)		4,691,734		8,280,633

SHAREHOLDERS' EQUITY (Tables)

6 Months Ended

Jun. 30, 2020

Disclosure of classes of share capital [abstract]

Schedule of Share Capital

As of December 31, 2019 and June 30, 2020, the Company’s share capital is composed of ordinary shares, as follows:

	Number of ordinary shares
	December 31,		June 30,
	2019		2020

Authorized share capital		500,000,000		500,000,000

Issued and paid-up share capital		171,269,528		296,508,550

	In USD and NIS
	December 31,		June 30,
	2019		2020

Authorized share capital (in NIS)		50,000,000		50,000,000

Issued and paid-up share capital (in NIS)		17,126,953		29,650,855

Issued and paid-up share capital (in USD)		4,691,734		8,280,633

GENERAL INFORMATION (Narrative) (Details) - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Disclosure of general information [Abstract]
Accumulatewd losses	$ (261,381)	$ (247,966)

AT-THE-MARKET (ATM) SALES AGREEMENT WITH BTIG (Details) - USD ($) $ in Thousands	1 Months Ended	6 Months Ended
	Apr. 30, 2020	Jun. 30, 2020	Jun. 30, 2019	Oct. 31, 2017
Disclosure of terms and conditions of share-based payment arrangement [line items]
Proceeds from shares issued		$ 13,411	$ 15,879
BTIG, LLC [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Aggregate offering price				$ 30,000
Percentage of commission on sales agreement				3.00%
Share purchase agreement, shares		2,923,552
Available balance under the facility	$ 8,500
Number of shares issued		676,750
Proceeds from shares issued		$ 13,000
Net proceeds from shares issued		$ 1,400

FINANCINGS (Narrative) (Details) - USD ($)	1 Months Ended
FINANCINGS (Narrative) (Details) - USD ($)	Jun. 30, 2020	May 31, 2020
Disclosure of terms and conditions of share-based payment arrangement [line items]
Underwritten public offering	2,510,286	5,142,859
Public offering price	$ 1.75	$ 1.75
Underwriter placement fee	125,514	257,143
Proceeds from public offering, gross	$ 4,400,000	$ 9,000,000
Proceeds from public offering, net	$ 3,900,000	$ 8,100,000
Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Exercise price of shares issued	$ 2.25	$ 2.25
Exercisable term of warrant	2.5 Years	2.5 Years
Exercise price of granted issued	$ 2.1875	$ 2.1875
Loan Agreement With Kreos Capital [Member] \| Warrants [Member]
Disclosure of terms and conditions of share-based payment arrangement [line items]
Risk-free interest rate (%)	0.23%	0.20%
Average standard deviation	80.90%	80.20%

SHAREHOLDERS' EQUITY (Schedule of Share Capital) (Details) ₪ in Thousands, $ in Thousands	Jun. 30, 2020 USD ($) shares	Jun. 30, 2020 ILS (₪) shares	Dec. 31, 2019 USD ($) shares	Dec. 31, 2019 ILS (₪) shares
Number of Ordinary Shares
Authorized share capital \| shares	500,000,000	500,000,000	500,000,000	500,000,000
Issued and paid-up share capital \| shares	296,508,550	296,508,550	171,269,528	171,269,528
Issued and paid-up share capital \| $	$ 8,280,633		$ 4,691,734
NIS [Member]
Number of Ordinary Shares
Authorized share capital \| ₪		₪ 50,000,000		₪ 50,000,000
Issued and paid-up share capital \| ₪		₪ 29,650,855		₪ 17,126,953